Skip to main content
. 2022 Aug 11;2022:3287961. doi: 10.1155/2022/3287961

Table 2.

DCR of patients with osteosarcoma using anlotinib as first-line therapy, second-line therapy, or beyond second-line therapy.

Treatment line DCR
Anlotinib Anlotinib plus chemotherapy Total
First line 0 (0/0) 0 (0/2) 0 (0/2)
Second line 50 (2/4) 75 (3/4) 63 (5/8)
Beyond second line 67 (2/3) 0 (0/0) 67 (2/3)
Total 57 (4/7) 50 (3/6) 54 (7/13)